Keywords: genentech, reports, solid, results, boosted, avastin, analysts
Genentech reports solid results for 2008 boosted by Avastin, but analysts negative
Article | 26 January 2009
US biotechnology giant Genentech reported solid figures for full-year 2008 in the shadow of a potential full takeover by Swiss majority ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
